MEDIVIR AB – FINANCIAL STATEMENT, JANUARY – DECEMBER 2016

Significant events during the fourth quarter · Medivir focuses research and development operations exclusively on oncology and reorganises in order to achieve significant cost savings. As a result of the operative transformation a non-recurring sum of SEK 49.1 million was charged to the profit/loss for the period and of SEK 52.6 million for the full year. · Medivir divests its pharmaceutical company, BioPhausia (Nordic Brands), to Karo Pharma for SEK 908 million and reports a consolidated capital gain of SEK 534.8 million, thereby applying IFRS 5 (see p. 12). · Medivir